Aug 8 (Reuters) - Endo International PLC ENDP.O :
* ENDO REPORTS SECOND-QUARTER 2018 FINANCIAL RESULTS
* Q2 ADJUSTED EARNINGS PER SHARE $0.76 FROM CONTINUING OPERATIONS
* Q2 GAAP LOSS PER SHARE $0.23 FROM CONTINUING OPERATIONS
* Q2 REVENUE $715 MILLION VERSUS I/B/E/S VIEW $678.3 MILLION
* Q2 EARNINGS PER SHARE VIEW $0.54 -- THOMSON REUTERS I/B/E/S
* COMPANY RAISES 2018 FINANCIAL GUIDANCE
* SEES 2018 TOTAL REVENUES TO BE BETWEEN $2.75 BILLION AND $2.85 BILLION
* SEES 2018 ADJUSTED DILUTED EPS FROM CONTINUING OPERATIONS TO BE BETWEEN $2.50 AND $2.60
* PHASE 3 TRIALS FOR COLLAGENASE CLOSTRIDIUM HISTOLYTICUM (CCH) EXPECTED TO HAVE TOP-LINE RESULTS IN FOURTH-QUARTER 2018